ATXN2 and amyotrophic lateral sclerosis: Our findings are relevant for ongoing clinical trials that recruit amyotrophic lateral sclerosis patients with repeat expansions in ATXN2 (Clinical Trial NCT04494256), where a drug that reduces the level of ataxin-2 protein is under investigation.